Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | PHGDH | O43175 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539755 | 0.81 | ABL1 (0.72) | ABL1RAB9AMAPTALDH1A1PHGDH | |
| SCHEMBL15688619 | 0.81 | MAPT (0.66) | ABL1RAB9AMAPTALDH1A1PHGDH | |
| SCHEMBL27626793 | 0.80 | ABL1 (0.67) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL4874135 | 0.80 | ABL1 (0.62) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL4865694 | 0.79 | AOC3 (0.61) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL6390644 | 0.78 | ABL1 (0.60) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL4875755 | 0.78 | ABL1 (0.60) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL15689027 | 0.77 | MAPT (0.70) | ABL1RAB9AMAPTALDH1A1PHGDH | |
| SCHEMBL6390650 | 0.76 | ABL1 (0.57) | ABL1RAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL4987542 | 0.76 | CLK1 (0.55) | ABL1RAB9AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | ABL1 1126/4885RAB9A 2542/4885MAPT 3135/4885 |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | ABL1 1126/4885RAB9A 2542/4885MAPT 3135/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | ABL1 1145/4885RAB9A 2075/4885MAPT 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.